| 5.8 0.38 (7.01%) | 05-21 11:48 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 6.8  |
1-year : | 7.95 |
| Resists | First : | 5.82 |
Second : | 6.8 |
| Pivot price | 4.72 |
|||
| Supports | First : | 4.73 |
Second : | 4.05 |
| MAs | MA(5) : | 5.31 |
MA(20) : | 4.87 |
| MA(100) : | 6.25  |
MA(250) : | 8.48 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 87.4 |
D(3) : | 78.9 |
| RSI | RSI(14): 60.6 |
|||
| 52-week | High : | 12.75 | Low : | 4.05 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SHLT ] has closed It is unclear right now based on current values. 61.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5.51 - 5.53 | 5.53 - 5.55 |
| Low: | 5.36 - 5.39 | 5.39 - 5.41 |
| Close: | 5.37 - 5.42 | 5.42 - 5.46 |
SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. The company offers smartheart, a personal mobile 12 lead ECG device that enables the detection of heart attacks; CardioSen'C, a personal cellular-digital 12-lead ECG transmitter device; Cardio'B, a portable device to transmit a 12-lead ECG; and Cardio Beeper 12/12, a hand-held ECG transmitter device for personal use that transmits a full ECG reading to the monitoring center. It also provides central communication module, a telecommunication device that transmits medical data to its telemedicine centers from various medical monitoring devices; TeleWeight, a trans-telephonic weight monitoring device for personal use; TelePress, a remote blood pressure monitoring device for personal use; TeleBreather, a remote electronic handheld device to test the working of lungs; and TelePulse Oximeter, an electronic handheld diagnostic device to measure the saturation level of oxygen in blood, as well as pulse rate. The company offers its telemedicine services and devices to subscribers using telephonic and internet communication technology. It serves patients, health insurance companies, hospitals, clinics, physicians, and other health care providers. The company has a collaboration agreement with Mayo Clinic to evaluate the incidence of emergency department visits, re-hospitalizations, and major adverse cardiovascular events over a period of 90 days after first hospitalization for a heart attack for patients using SmartHeart FDA approved 12 lead ECG; and collaboration agreement with the Hebrew University of Jerusalem and the Hadassah Medical Center to develop an artificial intelligence tool for predicting future life-threatening cardiac events based on 12 Lead ECG monitoring. SHL Telemedicine Ltd. was founded in 1987 and is headquartered in Tel Aviv, Israel.
Tue, 21 May 2024
SHL Telemedicine Expands Offering in Israel With Groundbreaking At-home Biomarker Blood Test - Business Wire
Thu, 16 May 2024
SHL Telemedicine Announces Official Launch of SmartHeart® D2C Membership in the US Following Successful Soft ... - Business Wire
Sat, 11 May 2024
SHL Telemedicine Ltd. (NASDAQ:SHLT) Short Interest Update - MarketBeat
Wed, 17 Apr 2024
SHL Announces Full-Year 2023 Results - Stable Revenue Growth Alongside Groundbreaking Clinical Milestones - Business Wire
Thu, 11 Apr 2024
Imperial College London Study Shows Groundbreaking Final Results for SHL Telemedicine's SmartHeart® in Post ... - Business Wire
Mon, 08 Apr 2024
SHL Telemedicine's SmartHeart® Technology Triumphs in US Army Project Convergence – Capstone 4 Experiment - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 16 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 8.3 (%) |
| Held by Institutions | 3.8 (%) |
| Shares Short | 1 (K) |
| Shares Short P.Month | 3 (K) |
| EPS | -0.55 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.48 |
| Profit Margin | -12.4 % |
| Operating Margin | -11.9 % |
| Return on Assets (ttm) | -4.4 % |
| Return on Equity (ttm) | -10.2 % |
| Qtrly Rev. Growth | -0.2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 3.48 |
| EBITDA (p.s.) | -0.33 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -2 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -10.75 |
| PEG Ratio | 0 |
| Price to Book value | 1.29 |
| Price to Sales | 1.66 |
| Price to Cash Flow | -63.38 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|